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Abstract
Background: Preeclampsia is a severe complication of pregnancy characterized by an excessive maternal systemic
inflammatory response with activation of both the innate and adaptive arms of the immune system. Cytokines,
chemokines and adhesion molecules are central to innate and adaptive immune processes. The purpose of this
study was to determine circulating levels of cytokines, chemokines and adhesion molecules in normal pregnancy
and preeclampsia in a comprehensive manner, and to investigate their relationship to the clinical features and
laboratory parameters of the study participants, including markers of overall inflammation (C-reactive protein),
endothelial activation (von Willebrand factor antigen) and endothelial injury (fibronectin), oxidative stress
(malondialdehyde) and trophoblast debris (cell-free fetal DNA).
Results: Serum levels of interleukin (IL)-1beta, IL-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-
12p70, IL-18, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta1,
interferon-gamma-inducible protein (IP)-10, monocyte chemotactic protein (MCP)-1, intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 were measured in 60 preeclamptic patients, 60 healthy
pregnant women and 59 healthy non-pregnant women by multiplex suspension array and ELISA. In normal
pregnancy, the relative abundance of circulating IL-18 over IL-12p70 and the relative deficiency of the bioactive IL-
12p70 in relation to IL-12p40 might favour Th2-type immunity. Although decreased IL-1ra, TNF-alpha and MCP-1
concentrations of healthy pregnant relative to non-pregnant women reflect anti-inflammatory changes in
circulating cytokine profile, their decreased serum IL-10 and increased IP-10 levels might drive pro-inflammatory
responses. In addition to a shift towards Th1-type immunity (expressed by the increased IL-2/IL-4 and IFN-gamma/
IL-4 ratios), circulating levels of the pro-inflammatory cytokines IL-6 and TNF-alpha, the chemokines IL-8, IP-10 and
MCP-1, as well as the adhesion molecules ICAM-1 and VCAM-1, were raised in preeclampsia compared with
healthy pregnancy, resulting in an overall pro-inflammatory systemic environment. Increased IP-10, MCP-1, ICAM-1
and VCAM-1 concentrations of preeclamptic patients showed significant correlations with blood pressure values,
renal and liver function parameters, as well as with CRP, malondialdehyde, von Willebrand factor antigen and
fibronectin levels.
Conclusions: According to our findings, preeclampsia was associated with an overall pro-inflammatory systemic
environment. Elevated amounts of pro-inflammatory cytokines, chemokines and adhesion molecules in the
maternal circulation might play a central role in the excessive systemic inflammatory response, as well as in the
generalized endothelial dysfunction characteristics of the maternal syndrome of preeclampsia.
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Preeclampsia, characterized by hypertension and protei-
nuria developing after midgestation, is a severe complica-
tion of human pregnancy with a worldwide incidence of
2-10%. It is one of the leading causes of maternal, as well
as perinatal morbidity and mortality, even in developed
countries. Despite intensive research efforts, the etiology
and pathogenesis of preeclampsia are not completely
understood. Increasing evidence suggests that an exces-
sive maternal systemic inflammatory response to preg-
nancy with activation of both the innate and adaptive
arms of the immune system is involved in the pathogen-
esis of the disease [1,2]. The development of preeclamp-
sia is influenced by both genetic and environmental risk
factors, suggesting its multifactorial inheritance [3-8].
An important feature of systemic inflammation in
preeclampsia is the absence of Th2 skewness character-
istic for healthy pregnancy, and thus the predominance
of Th1-type immunity. Saito et al. reported firstly that
the percentage of Th1 cells and the ratios of Th1/Th2
were significantly higher, while the percentage of Th2
cells was significantly lower in the peripheral blood in
preeclampsia than in the third trimester of normal preg-
nancy [9]. In another study, this group observed
increased production of interleukin (IL)-2, interferon
(IFN)-g and tumor necrosis factor (TNF)-a by periph-
eral blood mononuclear cells (PBMCs) in preeclampsia
and, interestingly, positive correlations between mean
blood pressure and concentrations of Th1 cytokines
[10]. The shift to a predominant Th1-type immunity in
preeclampsia was reinforced by other experiments on
intracellular cytokine measurements in peripheral blood
T (both helper and cytotoxic) cells and NK cells, as well
as by assessment of cytokine secretion levels of PBMCs
isolated from preeclamptic patients [11-14]. However,
the studies on circulating levels of cytokines in normal
pregnancy and preeclampsia yielded conflicting results
[15,16]. The discrepancies may be due to different tech-
niques used for cytokine detection, differences in the
ethnicity of the study populations, disease severity or
sample sizes.
The aim of this study was to determine circulating
levels of cytokines, chemokines and adhesion molecules
in a comprehensive manner involving a large number of
healthy non-pregnant and pregnant women and pree-
clamptic patients. We also measured several markers of
processes involved in the pathogenesis of preeclampsia,
and investigated whether serum cytokine, chemokine
and adhesion molecule levels were related to the clinical
characteristics and laboratory parameters of the study
participants, including markers of overall inflammation
(C-reactive protein), endothelial activation (von Willeb-
rand factor antigen) and endothelial injury (fibronectin),
oxidative stress (malondialdehyde) and trophoblast deb-
ris (cell-free fetal DNA).
Methods
Study patients
Our study was designed using a case-controlled
approach. Sixty preeclamptic patients, 60 healthy preg-
nant women with uncomplicated pregnancies and 59
healthy non-pregnant women were involved in the
study. The study participants were enrolled in the First
Department of Obstetrics and Gynecology and in the
Department of Obstetrics and Gynecology of Kútvölgyi
Clinical Center, at the Semmelweis University, Budapest,
Hungary. All women were Caucasian and resided in the
same geographic area in Hungary. Exclusion criteria
were multifetal gestation, chronic hypertension, diabetes
mellitus, autoimmune disease, angiopathy, renal disor-
der, maternal or fetal infection and fetal congenital
anomaly. The women were fasting, none of the pregnant
w o m e nw e r ei na c t i v el a b o r ,a n dn o n eh a dr u p t u r eo f
membranes. The healthy non-pregnant women were in
the early follicular phase of the menstrual cycle
(between cycle days 3 and 5), and none of them received
hormonal contraception.
Preeclampsia was defined by increased blood pressure
(≥140 mmHg systolic or ≥90 mmHg diastolic on ≥2
occasions at least 6 hours apart) that occurred after 20
weeks of gestation in a woman with previously normal
blood pressure, accompanied by proteinuria (≥0.3 g/24 h
or ≥1 + on dipstick in the absence of urinary tract infec-
tion). Blood pressure returned to normal by 12 weeks
postpartum in each preeclamptic study patient. Pree-
clampsia was regarded as severe if any of the following
criteria was present: blood pressure ≥160 mmHg systolic
or ≥110 mmHg diastolic, or proteinuria ≥5g / 2 4h( o r
≥3 + on dipstick). Pregnant women with eclampsia or
HELLP syndrome (hemolysis, elevated liver enzymes,
and low platelet count) were not enrolled in this study.
Early onset of preeclampsia was defined as onset of the
disease before 34 weeks of gestation (between 20 and 33
completed gestational weeks). Fetal growth restriction
was diagnosed if the fetal birth weight was below the
10
th percentile for gestational age and gender, based on
Hungarian birth weight percentiles [17].
The study protocol was approved by the Regional and
Institutional Committee of Science and Research Ethics
of the Semmelweis University, and written informed con-
sent was obtained from each patient. The study was con-
ducted in accordance with the Declaration of Helsinki.
Biological samples
Blood samples were taken from an antecubital vein into
plain, as well as EDTA- or sodium citrate anticoagulated
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relative centrifugal force of 3000 g for 10 minutes. The
aliquots of serum and plasma were stored at -80°C until
the analyses.
Laboratory methods
Serum levels of IL-1b, IL-1 receptor antagonist (IL-1ra),
IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-12p70, IL-18,
IFN-g,T N F - a, interferon-g-inducible protein (IP)-10,
monocyte chemotactic protein (MCP)-1, intercellular
adhesion molecule (ICAM)-1 and vascular cell adhesion
molecule (VCAM)-1 were measured by multiplex suspen-
sion array (Bio-Plex, Cat. No. X500317TGY and
XF0000ZGAI) on a Bio-Plex 200 analyzer (Bio-Rad
Laboratories, Hercules, California, USA). Levels of trans-
forming growth factor (TGF)-b1 in maternal sera were
assessed by ELISA (DRG International, Mountainside,
New Jersey, USA, Cat. No. EIA-1864). Standard laboratory
parameters (clinical chemistry) and C-reactive protein
(CRP) levels were determined by an autoanalyzer (Cobas
Integra 800, Roche, Mannheim, Germany) using the man-
ufacturer’s kits. Plasma von Willebrand factor antigen
(VWF:Ag) levels were quantified by ELISA (Dakopatts,
Glostrup, Denmark), while plasma fibronectin concentra-
tion by nephelometry (Dade Behring, Marburg, Germany),
according to the manufacturer’s instructions. After
extracting DNA with the silica adsorption method, the
amount of cell-free fetal DNA in maternal plasma was
determined in patients with male newborns by quantita-
tive real-time PCR analysis of the sex-determining region
Y (SRY) gene, as we described previously [18]. Plasma
malondialdehyde levels were measured by the thiobarbitu-
ric acid-based colorimetric assay [19].
Statistical analysis
The normality of continuous variables was assessed
using the Shapiro-Wilk’s W-test. As the continuous vari-
ables were not normally distributed, nonparametric sta-
tistical methods were used. To compare continuous
variables between two groups, the Mann-Whitney U-
test was applied, whereas to compare them among mul-
tiple groups, the Kruskal-Wallis analysis of variance by
ranks test was performed. Multiple comparisons of
mean ranks for all groups were carried out as post-hoc
tests. The Fisher exact and Pearson c
2 tests were used
to compare categorical variables between groups. The
Spearman rank order correlation was applied to calcu-
late correlation coefficients.
Statistical analyses were performed using the following
software: STATISTICA (version 8.0; StatSoft, Inc.,
Tulsa, Oklahoma, USA) and Statistical Package for the
Social Sciences (version 15.0 for Windows; SPSS, Inc.,
Chicago, Illinois, USA). For all statistical analyses, p <
0.05 was considered statistically significant.
In the article, data are reported as median (25-75 per-
centile) for continuous variables and as number (percen-
tage) for categorical variables.
Results
Patient characteristics
The clinical characteristics of the study participants are
described in Table 1. There was no statistically signifi-
cant difference in terms of age among the study groups.
Furthermore, no significant differences were observed in
gestational age at blood collection and the percentage of
primiparas between preeclamptic patients and healthy
pregnant women. However, all of the other clinical fea-
tures presented in Table 1 differed significantly among
our study groups. Fetal growth restriction was absent in
healthy pregnant women, whereas the frequency of this
condition was 18.3% in the preeclamptic group. Twenty-
one women had severe preeclampsia and 5 patients
experienced early onset of the disease.
Laboratory parameters
The laboratory parameters of the study subjects are dis-
played in Table 2. As can be seen in the table, there
were significant differences in most of the measured
laboratory parameters among the three study groups
except for serum aspartate aminotransferase (AST)
activity. Circulating levels of cytokines, chemokines and
adhesion molecules are shown in Table 3. Apart from
serum IL-1b and TGF-b1 levels, all of the measured
inflammatory variables differed significantly among our
study groups.
There were no significant differences in the ratios of
IL-2 to IL-4 and IFN-g to IL-4 between healthy non-
pregnant and pregnant women, whereas these ratios
were significantly increased in preeclamptic patients as
compared to healthy pregnant women (Figure 1, 2). On
the contrary, IL-18/IL-12p70 ratios were significantly
higher, while IL-12p70/IL-12p40 ratios were significantly
lower in healthy pregnant than in non-pregnant women,
but they showed the same level in preeclamptic patients
compared with healthy pregnant women (Figure 3, 4).
In the group of preeclamptic patients, no statistically
significant differences were found in serum levels of the
measured cytokines, chemokines and adhesion mole-
cules between patients with mild and severe preeclamp-
sia, between patients with late and early onset of the
disease, or between preeclamptic patients with and with-
out fetal growth restriction (data not shown).
Relationship of serum cytokine, chemokine and adhesion
molecule levels of the study subjects with their clinical
characteristics and laboratory parameters
We also investigated whether serum cytokine, chemo-
kine and adhesion molecule levels of the study
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laboratory parameters by calculating the Spearman rank
order correlation coefficients (continuous variables) or
by the Mann-Whitney U-test (categorical variables). In
healthy non-pregnant women, serum IL-6 and TNF-a
concentrations correlated significantly with CRP levels
(Spearman R = 0.28 and 0.29, respectively, p < 0.05). In
the group of healthy pregnant women, we found statisti-
cally significant negative correlations between serum
IL-2 and IFN-g concentrations and gestational age at
delivery (R = -0.27 and -0.29, respectively, p < 0.05).
A significant positive correlation was observed between
IL-6 and CRP levels of healthy pregnant women (R =
0.45, p < 0.05), while their TGF-b1 and malondialdehyde
concentrations correlated inversely with each other (R =
-0.38, p < 0.05). Serum IP-10 levels of healthy pregnant
women showed significant positive correlations with
serum creatinine levels (R = 0.53, p < 0.05), as well as
with plasma levels of VWF:Ag (R = 0.54, p < 0.001) and
fibronectin (R = 0.42, p < 0.05), while a significant
Table 1 Clinical characteristics of healthy non-pregnant and pregnant women and preeclamptic patients
Healthy non-pregnant women
(n = 59)
Healthy pregnant women
(n = 60)
Preeclamptic patients
(n = 60)
Age (years) 28 (23-35) 30 (28-32) 29 (26-32)
BMI at blood draw (kg/m
2) 20.8 (19.6-22.9) 25.8 (24.3-27.9)
b 29.9 (26.9-33.3)
b,d
Smokers 14 (23.7%) 0 (0%)
b 3 (5.0%)
a
Primiparas n.a. 37 (61.7%) 38 (63.3%)
Systolic blood pressure at blood draw (mmHg) 115 (110-120) 110 (107-120) 162 (155-180)
b,d
Diastolic blood pressure at blood draw (mmHg) 80 (70-80) 70 (60-80)
b 100 (97-110)
b,d
Gestational age at blood draw (weeks) n.a. 36 (36-37) 37 (36-39)
Gestational age at delivery (weeks) n.a. 39 (38-40) 38 (37-39)
d
Fetal birth weight (grams) n.a. 3450 (3150-3700) 3125 (2450-3475)
d
Fetal growth restriction n.a. 0 (0%) 11 (18.3%)
d
Data are presented as median (25-75 percentile) for continuous variables and as number (percentage) for categorical variables
n.a.: not applicable; BMI: body mass index
a p < 0.05 versus healthy non-pregnant women
b p < 0.001 versus healthy non-pregnant women
c p < 0.05 preeclamptic patients versus healthy pregnant women
d p < 0.001 preeclamptic patients versus healthy pregnant women
Table 2 Laboratory parameters of healthy non-pregnant and pregnant women and preeclamptic patients
Healthy non-pregnant women
(n = 59)
Healthy pregnant women
(n = 60)
Preeclamptic patients
(n = 60)
Serum BUN level (mmol/l) 4.1 (3.5-4.8) 2.8 (2.0-3.3)
b 3.5 (2.7-4.2)
a,c
Serum creatinine level (μmol/l) 66 (61-72) 49 (42-56)
b 63 (55-71)
d
Serum bilirubin level (μmol/l) 9.3 (6.6-12.4) 5.4 (4.0-6.8)
b 7.3 (5.7-8.9)
a,c
Serum AST activity (U/l) 17 (15-20) 19 (17-21) 19 (15-25)
Serum ALT activity (U/l) 14 (12-17) 12 (10-15)
a 16 (11-23)
c
Serum LDH activity (U/l) 154 (128-170) 158 (138-169) 192 (153-225)
b,d
Serum CRP level (mg/l) 0.7 (0.5-1.8) 3.6 (1.7-6.6)
b 6.8 (2.7-12.1)
b,c
Plasma VWF:Ag level (%) 70.0 (60.2-87.3) 152.6 (112.7-199.0)
b 184.8 (139.9-243.1)
b,c
Plasma fibronectin level (g/l) n.m. 0.37 (0.31-0.47) 0.58 (0.41-0.82)
d
Plasma malondialdehyde level (nmol/ml) n.m. 15.4 (8.8-18.6) 18.3 (15.6-20.4)
c
Plasma cell-free fetal DNA level (pg/μl) n.m. 0.002 (0.0-0.172)
† 0.082 (0.033-0.292)
‡,c
Data are presented as median (25-75 percentile)
n.m.: not measured; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; CRP: C-reactive
protein; VWF:Ag: von Willebrand factor antigen; DNA: deoxyribonucleic acid
† n=1 9
‡ n=3 3
a p < 0.05 versus healthy non-pregnant women
b p < 0.001 versus healthy non-pregnant women
c p < 0.05 preeclamptic patients versus healthy pregnant women
d p < 0.001 preeclamptic patients versus healthy pregnant women
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0.05). Furthermore, there were significant positive corre-
lations between their serum MCP-1 concentrations and
serum creatinine (R = 0.39, p < 0.05), as well as plasma
fibronectin levels (R = 0.48, p < 0.001). Significant corre-
lations between inflammatory variables of preeclamptic
patients and their clinical characteristics and laboratory
parameters are presented in Table 4. There was no
Table 3 Serum levels (pg/ml) of cytokines, chemokines and adhesion molecules in healthy non-pregnant and pregnant
women and preeclamptic patients
Healthy non-pregnant women (n = 59) Healthy pregnant women (n = 60) Preeclamptic patients (n = 60)
IL-1b 24.5 (23.0-28.0) 27.0 (23.0-31.5) 28.0 (23.0-34.0)
IL-1ra 8.0 (6.7-11.0) 6.0 (5.0-7.0)
b 18.0 (11.0-27.5)
b,d
IL-2 5.0 (4.2-6.0) 4.0 (4.0-5.0)
a 7.5 (5.5-12.0)
b,d
IL-4 3.0 (2.0-3.0) 2.0 (2.0-2.0)
b 3.0 (3.0-4.0)
b,d
IL-6 6.0 (5.0-8.0) 7.0 (5.0-9.0) 15.5 (12.0-32.0)
b,d
IL-8 23.0 (18.2-37.5) 24.5 (16.0-68.5) 78.0 (35.0-273)
b,d
IL-10 43.7 (32.7-60.5) 15.7 (14.0-19.0)
b 23.0 (18.0-35.0)
b,d
IL-12p40 119 (109-140) 136 (118-168)
a 185 (153-215)
b,d
IL-12p70 12.0 (9.0-15.0) 5.0 (4.0-5.0)
b 6.0 (5.0-8.0)
b,d
IL-18 38.7 (33.0-46.5) 56.0 (44.0-73.7)
b 73.5 (55.0-87.0)
b,c
IFN-g 4.0 (3.0-4.0) 3.0 (2.0-3.0)
b 5.0 (4.0-6.0)
b,d
TNF-a 2.0 (2.0-3.0) 2.0 (1.0-2.0)
a 2.0 (2.0-3.0)
d
TGF-b1 342 (285-388) 364 (307-413) 383 (331-418)
IP-10 198 (142-327) 327 (222-442)
b 688 (434-928)
b,d
MCP-1 153 (87.5-233) 79.5 (52.5-110)
b 189 (120-283)
d
ICAM-1 6638 (6143-7205) 6789 (6201-7672) 8132 (7413-8808)
b,d
VCAM-1 6151 (5767-6564) 6157 (5633-6617) 7386 (6913-7709)
b,d
Data are presented as median (25-75 percentile)
IL: interleukin; IL-1ra: IL-1 receptor antagonist; IFN: interferon; TNF: tumor necrosis factor; TGF: transforming growth factor; IP: interferon-g-inducible protein; MCP:
monocyte chemotactic protein; ICAM: intercellular adhesion molecule; VCAM: vascular cell adhesion molecule
a p < 0.05 versus healthy non-pregnant women
b p < 0.001 versus healthy non-pregnant women
c p < 0.05 preeclamptic patients versus healthy pregnant women
d p < 0.001 preeclamptic patients versus healthy pregnant women
Figure 1 IL(interleukin)-2/IL-4 ratios of healthy non-pregnant
and pregnant women and preeclamptic patients. Middle point:
median; Box: interquartile range (25-75 percentile); Whisker: range
(excluding outliers);
a p < 0.001 versus healthy non-pregnant
women;
b p < 0.05 versus healthy pregnant women.
Figure 2 IFN(interferon)-g/IL(interleukin)-4 ratios of healthy
non-pregnant and pregnant women and preeclamptic patients.
Middle point: median; Box: interquartile range (25-75 percentile);
Whisker: range (excluding outliers);
a p < 0.05 versus healthy
pregnant women.
Szarka et al. BMC Immunology 2010, 11:59
http://www.biomedcentral.com/1471-2172/11/59
Page 5 of 9other relationship between serum cytokine, chemokine
and adhesion molecule levels of the study subjects and
their clinical features and measured laboratory para-
meters in either study group.
Discussion
In this study, we determined circulating levels of several
cytokines, chemokines and adhesion molecules in
healthy non-pregnant and pregnant women and pree-
clamptic patients by high-throughput multiplex suspen-
sion array technology. Except for serum IL-1b and TGF-
b1 levels, all of the measured inflammatory variables dif-
fered significantly among the three study groups. Simul-
taneous measurement of several markers of disease
processes enabled us to explore their role in the patho-
genesis of preeclampsia.
Normal pregnancy is characterized by a shift towards
Th2-type immunity and the inhibition of cytotoxic
Th1 immune responses, which could be harmful to the
fetus (reflected by the inverse correlation of serum IL-
2a n dI F N - g levels with gestational age at delivery in
our healthy pregnant women) [20]. IL-18 and IL-12
are the key cytokines regulating Th1/Th2 balance. IL-
18 alone can induce Th2-type immunity, but in the
presence of IL-12, IL-18 stimulates Th1-mediated
immune responses [21]. Indeed, the ratios of IL-18 to
IL-12 secreted by PBMCs have been reported to be
significantly increased in normal pregnancy [22]. In
healthy pregnant women, the relative abundance of cir-
culating IL-18 over IL-12 expressed by the increased
serum IL-18/IL-12p70 ratios observed in our study, as
well as the relative deficiency of the bioactive IL-12p70
in relation to IL-12p40 (its competitive inhibitor)
reflected by the decreased serum IL-12p70/IL-12p40
ratios, might favour Th2-type immunity. In our pree-
clamptic patients, serum IL-12p70 levels were signifi-
cantly higher as compared to healthy pregnant women.
Although circulating IL-18 and IL-12p40 levels were
also elevated yielding similar IL-18/IL-12p70 and IL-
12p70/IL-12p40 ratios as in normal pregnancy, the
relative abundance of circulating IL-2 and IFN-g over
IL-4 - as shown by the increased serum IL-2/IL-4 and
IFN-g/IL-4 ratios - might provide a Th1-biased sys-
temic environment in preeclampsia.
In addition to changes in Th1/Th2 balance, several
other soluble inflammatory variables were also altered
in normal pregnancy and preeclampsia. Circulating
levels of the pro-inflammatory cytokines IL-6 and
TNF-a, the chemokines IL-8, IP-10 and MCP-1, as
well as the adhesion molecules ICAM-1 and VCAM-1,
were raised in preeclampsia compared with healthy
pregnancy, resulting in an overall pro-inflammatory
systemic environment. Elevated circulating IL-1 recep-
tor antagonist concentrations in preeclampsia reflect
increased activity of the pro-inflammatory cytokines
IL-1a and b, which have a very short half-life in the
circulation, and therefore it is difficult to detect a dif-
ference in their serum levels [23]. The increase in
levels of the immunoregulatory cytokine IL-10 in our
preeclamptic patients is in line with previous findings
and might be a compensatory phenomenon [24]. On
the other hand, the changes in circulating cytokine
profile in our healthy pregnant group were - at least in
part - anti-inflammatory as shown by the decreased
IL-1ra, TNF-a and MCP-1 concentrations relative to
Figure 3 IL(interleukin)-18/IL-12p70 ratios of healthy non-
pregnant and pregnant women and preeclamptic patients.
Middle point: median; Box: interquartile range (25-75 percentile);
Whisker: range (excluding outliers);
a p < 0.001 versus healthy non-
pregnant women.
Figure 4 IL(interleukin)-12p70/IL-12p40 ratios of healthy non-
pregnant and pregnant women and preeclamptic patients.
Middle point: median; Box: interquartile range (25-75 percentile);
Whisker: range (excluding outliers);
a p < 0.001 versus healthy non-
pregnant women.
Szarka et al. BMC Immunology 2010, 11:59
http://www.biomedcentral.com/1471-2172/11/59
Page 6 of 9non-pregnant women. However, decreased serum IL-10
and increased IP-10 levels found in our healthy preg-
nant women might drive pro-inflammatory responses.
Indeed, the third trimester of normal pregnancy seems
to be a controlled state of systemic inflammation, as
expressed also by the elevated serum CRP levels in our
study [25]. Interestingly, a state of controlled inflam-
mation at the feto-maternal interface in early preg-
nancy with production of pro-inflammatory cytokines
and chemokines is thought to be beneficial for tropho-
blast invasion [26,27]. Although serum concentrations
of TGF-b1 did not differ among our study groups, ele-
vated levels of its soluble co-receptor, endoglin, have
been observed in preeclampsia previously [28]. Soluble
endoglin impairs binding of TGF-b1 to its receptors
and downstream signalling, leading to dysregulated
TGF-b signalling in the vasculature.
The maternal systemic inflammatory response charac-
teristic of both the third trimester of normal pregnancy
and - in an excessive form - preeclampsia involves an
acute-phase reaction as well as systemic oxidative stress,
and circulating cytokines are central to these processes
[29]. Pro-inflammatory cytokines, primarily IL-6, can
induce an acute-phase response [30]. Furthermore, cyto-
kines can cause the release of oxygen free radicals,
whereas reactive oxygen metabolites can up-regulate the
genes that code for pro-inflammatory cytokines and
adhesion molecules [31]. Indeed, serum IL-6 (and TNF-
a) concentrations correlated with CRP levels in our
healthy non-pregnant and pregnant groups. The inverse
correlation between TGF-b1 and malondialdehyde levels
of our healthy pregnant women indicates that TGF-b1
could inhibit lipid peroxide production in normal preg-
nancy. Interestingly, serum MCP-1 and ICAM-1 con-
centrations showed significant positive correlations with
CRP and malondialdehyde levels in the group of pree-
clamptic patients, which implies that recruitment and
adhesion of leukocytes to endothelial cells are central
features of the generalized intravascular inflammatory
reaction and oxidative stress observed in preeclampsia.
The correlation of MCP-1 and ICAM-1 concentrations
with blood pressure values and liver function para-
meters, respectively, suggests that these cytokines and
the inflammatory processes they mediate might contri-
bute to the development of hypertension and hepatocel-
lular injury in this pregnancy-specific disorder.
Cytokines, chemokines and adhesion molecules could
be potential mediators of endothelial dysfunction, which
is a hallmark of the maternal syndrome of preeclampsia.
Therefore, we examined whether these inflammatory
variables were related to the markers of endothelial acti-
vation (von Willebrand factor antigen) and injury
Table 4 Significant correlations of serum cytokine, chemokine and adhesion molecule levels of preeclamptic patients
with their clinical characteristics and laboratory parameters
Correlation coefficient Statistical significance (p value)
IP-10 & BUN level 0.26 <0.05
IP-10 & creatinine level 0.43 <0.05
IP-10 & AST activity 0.46 <0.001
IP-10 & ALT activity 0.38 <0.05
IP-10 & LDH activity 0.38 <0.05
IP-10 & VWF:Ag level 0.35 <0.05
IP-10 & fibronectin level 0.37 <0.05
MCP-1 & systolic blood pressure 0.27 <0.05
MCP-1 & CRP level 0.27 <0.05
MCP-1 & malondialdehyde level 0.27 <0.05
ICAM-1 & bilirubin level 0.32 <0.05
ICAM-1 & AST activity 0.32 <0.05
ICAM-1 & LDH activity 0.37 <0.05
ICAM-1 & CRP level 0.30 <0.05
ICAM-1 & malondialdehyde level 0.31 <0.05
VCAM-1 & BUN level 0.30 <0.05
VCAM-1 & creatinine level 0.44 <0.001
VCAM-1 & AST activity 0.40 <0.05
VCAM-1 & LDH activity 0.56 <0.001
VCAM-1 & fibronectin level 0.41 <0.05
IP: interferon-g-inducible protein; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; LDH: lactate dehydrogenase; VWF:Ag: von
Willebrand factor antigen; MCP: monocyte chemotactic protein; CRP: C-reactive protein; ICAM: intercellular adhesion molecule; VCAM: vascular cell adhesion molecule
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Page 7 of 9(fibronectin). In this study, significant correlations were
found between IP-10, MCP-1 and VCAM-1 levels and
endothelial markers in normal pregnancy and pree-
clampsia. Certain organs with fenestrated (discontinu-
ous) endothelium, such as thek i d n e y( g l o m e r u l i ) ,l i v e r
(sinusoids) and brain (choroid plexus) are disproportion-
ally affected in preeclampsia. Interestingly, serum IP-10,
MCP-1 and VCAM-1 concentrations were also related
to renal and liver function parameters in our study.
These findings denote the central role of these inflam-
matory molecules in mediating endothelial damage. IP-
10 showed the strongest association with endothelial
dysfunction in our healthy pregnant women and pree-
clamptic patients. Indeed, IP-10 (CXCL10) has pro-
inflammatory and anti-angiogenic properties, and this
chemokine has been proposed to be a potential link
between inflammation and anti-angiogenesis in pree-
clampsia [32]. The inverse correlation of IP-10 levels
with fetal birth weight of healthy pregnant women sug-
gests its inhibitory role in placental angiogenesis.
Although TNF-a can also elicit endothelial cell dysfunc-
tion and injury, no significant relationship was observed
between its serum concentration and endothelial mar-
kers in this study [33]. Nevertheless, we did not measure
levels of soluble TNF receptors, which have a longer
half-life than TNF-a and, thus, are thought to be more
reliable markers of TNF-a activity.
The placenta is supposed to be a potential source of
circulating inflammatory cytokines in preeclampsia [34].
Interestingly, syncytiotrophoblast sheds placental debris
into the maternal circulation in preeclampsia with ele-
vated amounts. The mass of this trophoblast debris can
be assessed by the measurement of copies of cell-free
fetal DNA in the maternal plasma [35,36]. However, cir-
culating levels of cytokines and other inflammatory
molecules did not show a significant correlation with
those of cell-free fetal DNA in our study, indicating that
trophoblast deportation process may not substantially
contribute to the elevated circulating concentrations of
inflammatory molecules. Others have also questioned
that the placenta is the major source of pro-inflamma-
tory cytokines in the circulation of preeclamptic women
[37]. Indeed, dysfunctional maternal endothelial cells
and activated circulating leukocytes could also release
inflammatory molecules into the blood in this disorder.
Additionally, there is a strong genetic influence on cyto-
kine production. Therefore, genetic factors might also
account - at least partly - for the abnormal cytokine
profile observed in preeclampsia [4,38-41].
In this study, the similar cytokine profile of preeclamp-
tic patients regardless of the severity, the time of onset of
the disease or the presence of fetal growth restriction
might be explained by the multifactorial etiology of pree-
clampsia. Several genetic, behavioural and environmental
factors need to interact to produce the complete picture
of this pregnancy-specific disorder. Our research group
reported various genetic and soluble factors that were
associated with the severity or complications of pree-
clampsia, including HELLP syndrome and fetal growth
restriction [42-45]. Nevertheless, it is also possible that
the relatively small sample size of this study prevented to
detect an effect in the subgroup analyses.
Conclusions
According to our findings, preeclampsia was associated
with an overall pro-inflammatory systemic environment.
Elevated amounts of pro-inflammatory cytokines, che-
mokines and adhesion molecules in the maternal circu-
lation might play a central role in the excessive systemic
inflammatory response, as well as in the generalized
endothelial dysfunction characteristics of the maternal
syndrome of preeclampsia.
Acknowledgements
We thank Veronika Makó, László Cervenak, Krisztián Balogh and Miklós Mézes
for measuring plasma von Willebrand factor antigen and malondialdehyde
concentrations. This work was supported by a research grant from the
Faculty of Medicine of the Semmelweis University, as well as by the János
Bolyai Research Scholarship of the Hungarian Academy of Sciences.
Author details
1First Department of Obstetrics and Gynecology, Semmelweis University,
Budapest, Hungary.
2Central Laboratory, Semmelweis University, Budapest,
Hungary.
Authors’ contributions
ASZ collected data and drafted the manuscript. JR participated in the design
of the study. LL determined cell-free fetal DNA. GB carried out multiplex
suspension array measurements. AM conceived of the study, participated in
its design and coordination, performed statistical analyses and helped to
draft the manuscript. All authors read and approved the final manuscript.
Received: 25 August 2010 Accepted: 2 December 2010
Published: 2 December 2010
References
1. Redman CW, Sacks GP, Sargent IL: Preeclampsia: an excessive maternal
inflammatory response to pregnancy. Am J Obstet Gynecol 1999,
180:499-506.
2. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y: The role of the
immune system in preeclampsia. Mol Aspects Med 2007, 28:192-209.
3. Ohkuchi A, Iwasaki R, Suzuki H, Hirashima C, Takahashi K, Usui R,
Matsubara S, Minakami H, Suzuki M: Normal and high-normal blood
pressures, but not body mass index, are risk factors for the subsequent
occurrence of both preeclampsia and gestational hypertension: a
retrospective cohort study. Hypertens Res 2006, 29:161-167.
4. de Lima TH, Sass N, Mattar R, Moron AF, Torloni MR, Franchim CS, Daher S:
Cytokine gene polymorphisms in preeclampsia and eclampsia. Hypertens
Res 2009, 32:565-569.
5. Molvarec A, Kalabay L, Derzsy Z, Szarka A, Halmos A, Stenczer B, Arnaud P,
Karadi I, Prohaszka Z, Rigo J Jr: Preeclampsia is associated with decreased
serum alpha(2)-HS glycoprotein (fetuin-A) concentration. Hypertens Res
2009, 32:665-669.
6. Molvarec A, Derzsy Z, Kocsis J, Boze T, Nagy B, Balogh K, Mako V,
Cervenak L, Mezes M, Karadi I, Prohaszka Z, Rigo J Jr: Circulating anti-heat-
shock-protein antibodies in normal pregnancy and preeclampsia. Cell
Stress Chaperones 2009, 14:491-498.
Szarka et al. BMC Immunology 2010, 11:59
http://www.biomedcentral.com/1471-2172/11/59
Page 8 of 97. Aggarwal PK, Jain V, Jha V: Endothelial nitric oxide synthase, angiotensin-
converting enzyme and angiotensinogen gene polymorphisms in
hypertensive disorders of pregnancy. Hypertens Res 2010, 33:473-477.
8. Molvarec A, Tamasi L, Losonczy G, Madach K, Prohaszka Z, Rigo J Jr:
Circulating heat shock protein 70 (HSPA1A) in normal and pathological
pregnancies. Cell Stress Chaperones 2010, 15:237-247.
9. Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T: Quantitative
analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio
during normal human pregnancy and preeclampsia. Clin Exp Immunol
1999, 117:550-555.
10. Saito S, Umekage H, Sakamoto Y, Sakai M, Tanebe K, Sasaki Y, Morikawa H:
Increased T-helper-1-type immunity and decreased T-helper-2-type
immunity in patients with preeclampsia. Am J Reprod Immunol 1999,
41:297-306.
11. Ohkuchi A, Minakami H, Aoya T, Haga T, Kimura H, Suzuki M, Sato I:
Expansion of the fraction of Th1 cells in women with preeclampsia:
inverse correlation between the percentage of Th1 cells and the plasma
level of PAI-2. Am J Reprod Immunol 2001, 46:252-259.
12. Darmochwal-Kolarz D, Rolinski J, Leszczynska-Goarzelak B, Oleszczuk J: The
expressions of intracellular cytokines in the lymphocytes of preeclamptic
patients. Am J Reprod Immunol 2002, 48:381-386.
13. Darmochwal-Kolarz D, Leszczynska-Gorzelak B, Rolinski J, Oleszczuk J: T
helper 1- and T helper 2-type cytokine imbalance in pregnant women
with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1999, 86:165-170.
14. Azizieh F, Raghupathy R, Makhseed M: Maternal cytokine production
patterns in women with pre-eclampsia. Am J Reprod Immunol 2005,
54:30-37.
15. Jonsson Y, Ruber M, Matthiesen L, Berg G, Nieminen K, Sharma S,
Ernerudh J, Ekerfelt C: Cytokine mapping of sera from women with
preeclampsia and normal pregnancies. J Reprod Immunol 2006, 70:83-91.
16. Visser N, van Rijn BB, Rijkers GT, Franx A, Bruinse HW: Inflammatory
changes in preeclampsia: current understanding of the maternal innate
and adaptive immune response. Obstet Gynecol Surv 2007, 62:191-201.
17. Joubert K: Standards of the body mass and body length of birth in
Hungary on the basis of the 1990-1996 nation-wide liveborn data. Magy
Noorv L 2000, 63:155-163.
18. Lazar L, Nagy B, Ban Z, Nagy GR, Papp Z: Presence of cell-free fetal DNA
in plasma of women with ectopic pregnancies. Clin Chem 2006,
52:1599-1601.
19. Placer ZA, Cushman LL, Johnson BC: Estimation of product of lipid
peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem
1966, 16:359-364.
20. Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine
interactions in the maternal-fetal relationship: is successful pregnancy a
TH2 phenomenon? Immunol Today 1993, 14:353-356.
21. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 regulates
both Th1 and Th2 responses. Annu Rev Immunol 2001, 19:423-474.
22. Sakai M, Shiozaki A, Sasaki Y, Yoneda S, Saito S: The ratio of interleukin
(IL)-18 to IL-12 secreted by peripheral blood mononuclear cells is
increased in normal pregnant subjects and decreased in pre-eclamptic
patients. J Reprod Immunol 2004, 61:133-143.
23. Greer IA, Lyall F, Perera T, Boswell F, Macara LM: Increased concentrations
of cytokines interleukin-6 and interleukin-1 receptor antagonist in
plasma of women with preeclampsia: a mechanism for endothelial
dysfunction? Obstet Gynecol 1994, 84:937-940.
24. Benian A, Madazli R, Aksu F, Uzun H, Aydin S: Plasma and placental levels
of interleukin-10, transforming growth factor-beta1, and epithelial-
cadherin in preeclampsia. Obstet Gynecol 2002, 100:327-331.
25. Sacks GP, Studena K, Sargent K, Redman CW: Normal pregnancy and
preeclampsia both produce inflammatory changes in peripheral blood
leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998, 179:80-86.
26. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-
Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V,
Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O: Decidual NK
cells regulate key developmental processes at the human fetal-maternal
interface. Nat Med 2006, 12:1065-1074.
27. Fest S, Aldo PB, Abrahams VM, Visintin I, Alvero A, Chen R, Chavez SL,
Romero R, Mor G: Trophoblast-macrophage interactions: a regulatory
network for the protection of pregnancy. Am J Reprod Immunol 2007,
57:55-66.
28. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y,
Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D’Amore PA,
Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA:
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat
Med 2006, 12:642-649.
29. Redman CW, Sargent IL: Preeclampsia and the systemic inflammatory
response. Semin Nephrol 2004, 24:565-570.
30. Gabay C, Kushner I: Acute-phase proteins and other systemic responses
to inflammation. N Engl J Med 1999, 340:448-454.
31. Conner EM, Grisham MB: Inflammation, free radicals, and antioxidants.
Nutrition 1996, 12:274-277.
32. Gotsch F, Romero R, Friel L, Kusanovic JP, Espinoza J, Erez O, Than NG,
Mittal P, Edwin S, Yoon BH, Kim CJ, Mazaki-Tovi S, Chaiworapongsa T,
Hassan SS: CXCL10/IP-10: a missing link between inflammation and anti-
angiogenesis in preeclampsia? J Matern Fetal Neonatal Med 2007,
20:777-792.
33. Pober JS, Min W: Endothelial cell dysfunction, injury and death. Handb
Exp Pharmacol 2006, 135-156.
34. Rusterholz C, Hahn S, Holzgreve W: Role of placentally produced
inflammatory and regulatory cytokines in pregnancy and the etiology of
preeclampsia. Semin Immunopathol 2007, 29:151-162.
35. Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, Haines CJ,
Redman CW: Quantitative abnormalities of fetal DNA in maternal serum
in preeclampsia. Clin Chem 1999, 45:184-188.
36. Lazar L, Rigo J Jr, Nagy B, Balogh K, Mako V, Cervenak L, Mezes M,
Prohaszka Z, Molvarec A: Relationship of circulating cell-free DNA levels
to cell-free fetal DNA levels, clinical characteristics and laboratory
parameters in preeclampsia. BMC Med Genet 2009, 10:120.
37. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP: Expression of
inflammatory cytokines in placentas from women with preeclampsia. J
Clin Endocrinol Metab 2001, 86:2505-2512.
38. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, McKillop JH: Tumour
necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in
pre-eclampsia. Clin Exp Immunol 1996, 104:154-159.
39. Haggerty CL, Ferrell RE, Hubel CA, Markovic N, Harger G, Ness RB:
Association between allelic variants in cytokine genes and preeclampsia.
Am J Obstet Gynecol 2005, 193:209-215.
40. Daher S, Sass N, Oliveira LG, Mattar R: Cytokine genotyping in
preeclampsia. Am J Reprod Immunol 2006, 55:130-135.
41. Vural P, Degirmencioglu S, Saral NY, Demirkan A, Akgul C, Yildirim G,
Issever H, Eroglu H: Tumor necrosis factor alpha, interleukin-6 and
interleukin-10 polymorphisms in preeclampsia. J Obstet Gynaecol Res
2010, 36:64-71.
42. Molvarec A, Jermendy A, Nagy B, Kovacs M, Varkonyi T, Hupuczi P,
Prohaszka Z, Rigo J Jr: Association between tumor necrosis factor (TNF)-
alpha G-308A gene polymorphism and preeclampsia complicated by
severe fetal growth restriction. Clin Chim Acta 2008, 392:52-57.
43. Molvarec A, Rigo J Jr, Lazar L, Balogh K, Mako V, Cervenak L, Mezes M,
Prohaszka Z: Increased serum heat-shock protein 70 levels reflect
systemic inflammation, oxidative stress and hepatocellular injury in
preeclampsia. Cell Stress Chaperones 2009, 14:151-159.
44. Rosta K, Molvarec A, Enzsoly A, Nagy B, Ronai Z, Fekete A, Sasvari-Szekely M,
Rigo J Jr, Ver A: Association of extracellular superoxide dismutase (SOD3)
Ala40Thr gene polymorphism with pre-eclampsia complicated by severe
fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2009, 142:134-138.
45. Nagy B, Varkonyi T, Molvarec A, Lazar L, Hupuczi P, Than NG, Rigo J: Leptin
gene (TTTC)(n) microsatellite polymorphism in pre-eclampsia and HELLP
syndrome. Clin Chem Lab Med 2009, 47:1033-1037.
doi:10.1186/1471-2172-11-59
Cite this article as: Szarka et al.: Circulating cytokines, chemokines and
adhesion molecules in normal pregnancy and preeclampsia determined
by multiplex suspension array. BMC Immunology 2010 11:59.
Szarka et al. BMC Immunology 2010, 11:59
http://www.biomedcentral.com/1471-2172/11/59
Page 9 of 9